Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy...

Published on 20 Jun 2024 on Benzinga · via Yahoo Finance

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy...

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial

Lyell Immunopharma Inc (NASDAQ:LYEL) shares are trading lower on Wednesday on a heavy session volume of 5.79 million shares as per data from Benzinga Pro.

The company released initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology.

Read the rest of the article

NASDAQ.LYEL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy...

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial Lyell Im...

Benzinga · via Yahoo Finance 20 Jun 2024

Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an...

Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have sign...

Simply Wall St. via Yahoo Finance 17 Mar 2024

Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights

Net Loss: Reported a net loss of $52.9 million for Q4 and $234.6 million for the full year 2023.R...

GuruFocus.com via Yahoo Finance 28 Feb 2024

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold...

Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have sign...

Simply Wall St. via Yahoo Finance 9 Oct 2023

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Shareholders in Lyell Immunopharma, Inc. (NASDAQ:LYEL) may be thrilled to learn that the analysts...

Simply Wall St. via Yahoo Finance 29 Aug 2023

Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down...

Over the last month the Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been much stronger than before...

Simply Wall St. via Yahoo Finance 1 Jun 2023

There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues

Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) price-to-sales (or "P/S") ratio of 7x might make it look...

Simply Wall St. via Yahoo Finance 17 Apr 2023

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold...

Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price...

Simply Wall St. via Yahoo Finance 26 Mar 2023

Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.03 per share versus the Zacks Cons...

Zacks via Yahoo Finance 28 Feb 2023

Lyell Immunopharma (NASDAQ:LYEL) investors are sitting on a loss of 63% if they invested a year ago

The nature of investing is that you win some, and you lose some. And unfortunately for Lyell Immu...

Simply Wall St. via Yahoo Finance 23 Dec 2022

News

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy...

NASDAQ.LYEL price evolution

Want to become a better investor?